- Report
- March 2024
- 197 Pages
Global
From €3253EUR$3,374USD£2,782GBP
€3614EUR$3,749USD£3,091GBP
- Report
- January 2024
- 161 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Report
- March 2024
- 186 Pages
Global
From €3253EUR$3,374USD£2,782GBP
€3614EUR$3,749USD£3,091GBP
- Report
- October 2023
- 190 Pages
Global
From €4724EUR$4,900USD£4,040GBP
- Report
- December 2023
- 157 Pages
Global
€4816EUR$4,995USD£4,119GBP
- Report
- January 2021
- 900 Pages
United States
From €3182EUR$3,300USD£2,721GBP
- Report
- August 2022
- 120 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- March 2019
- 195 Pages
Global
From €10600EUR$10,995USD£9,066GBP
- Report
- May 2024
- 50 Pages
Global
From €2555EUR$2,650USD£2,185GBP
- Book
- July 2023
- 320 Pages
Raloxifene is a selective estrogen receptor modulator (SERM) used to treat and prevent breast cancer in postmenopausal women. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are at high risk for invasive breast cancer. Raloxifene works by blocking the effects of estrogen in breast tissue, which can help reduce the risk of breast cancer. It also helps to reduce the risk of fractures in postmenopausal women with osteoporosis.
Raloxifene is available in both oral and injectable forms. It is usually taken once a day, either with or without food. Common side effects of raloxifene include hot flashes, leg cramps, and joint pain.
Raloxifene is a widely used breast cancer drug, and is available from many pharmaceutical companies. Some of the companies that produce raloxifene include Pfizer, Novartis, and Mylan. Show Less Read more